NovaBay Pharmaceuticals (NYSE:NBY) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report released on Wednesday morning. The brokerage issued a sell rating on the stock.

NovaBay Pharmaceuticals Price Performance

Shares of NYSE NBY opened at $0.09 on Wednesday. NovaBay Pharmaceuticals has a 1 year low of $0.07 and a 1 year high of $1.28. The stock has a market capitalization of $3.42 million, a P/E ratio of -0.02 and a beta of 2.03. The company’s 50-day moving average is $0.11 and its 200 day moving average is $0.20.

NovaBay Pharmaceuticals (NYSE:NBY) last posted its quarterly earnings data on Tuesday, March 26th. The company reported ($0.95) earnings per share for the quarter. NovaBay Pharmaceuticals had a negative net margin of 65.46% and a negative return on equity of 150.14%. The firm had revenue of $3.73 million for the quarter. Research analysts anticipate that NovaBay Pharmaceuticals will post -0.41 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NovaBay Pharmaceuticals stock. Armistice Capital LLC bought a new stake in shares of NovaBay Pharmaceuticals, Inc. (NYSE:NBY) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 718,768 shares of the company’s stock, valued at approximately $147,000. Armistice Capital LLC owned approximately 11.01% of NovaBay Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 23.25% of the stock is owned by hedge funds and other institutional investors.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.